Compare RAIL & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAIL | SPRO |
|---|---|---|
| Founded | 1901 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.9M | 156.3M |
| IPO Year | 2005 | 2017 |
| Metric | RAIL | SPRO |
|---|---|---|
| Price | $9.28 | $2.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 170.6K | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.94 | 111.81 |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $500,991,000.00 | $66,802,000.00 |
| Revenue This Year | $6.54 | N/A |
| Revenue Next Year | $30.90 | $300.00 |
| P/E Ratio | $8.10 | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $7.27 | $1.80 |
| 52 Week High | $14.90 | $3.09 |
| Indicator | RAIL | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 67.91 | 38.98 |
| Support Level | $9.00 | $2.19 |
| Resistance Level | $10.09 | $2.47 |
| Average True Range (ATR) | 0.46 | 0.26 |
| MACD | 0.20 | -0.06 |
| Stochastic Oscillator | 86.71 | 29.54 |
FreightCar America Inc is a diversified manufacturer and supplier of railcars and railcar components. It designs and manufactures a variety of railcar types for transportation of bulk commodities and containerized freight products in North America. The company also provides railcar rebody and repair services, railcar conversion services, and supplies railcar parts. The company has two segments: Manufacturing and Aftermarket. The majority of the company's revenue is derived from the Manufacturing segment, which includes new railcar manufacturing, used railcar sales, and various conversions and rebodies. Geographically, it generates the maximum revenue from the United States.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.